A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy
Recurrent or Progressive
Sub-indication: Glioblastoma Multiforme
Line of Therapy: Second line post TMZ
Principal Investigator: Renato LaRocca, M.D.Norton Cancer Institute
Sponsor: Boston Biomedical, Inc.
Email for more information: CNS-NCIResearch@nortonhealthcare.org